CLINICAL TRIALS PROFILE FOR TRIMBOW
All Clinical Trials for TRIMBOW
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03662711 ↗ | Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease | Recruiting | Università degli Studi di Ferrara | Phase 4 | 2018-11-11 | This will be a phase IV, open label, multicenter, randomized pragmatic study in frail elderly patients with COPD. Participants will be treated with either inhaled LABD alone or LABD combined with inhaled glucocorticosteroids. The main aim of the study is to assess whether, in elderly patients with COPD and one or more cardiac comorbidities (heart failure, and/or ischemic heart disease, and/or atrial fibrillation) recently hospitalized because of an acute exacerbation of COPD, 12 months treatment with LABD(s)+ICS can increase the time to first re-hospitalization (all cause) and/or death for any cause when compared with LABD(s) alone. Patients will be followed-up for 3 months after completion of the 12 month treatment period. |
| NCT03795350 ↗ | Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients | Terminated | Chiesi Farmaceutici S.p.A. | Phase 1 | 2019-01-14 | The purpose of this study is to investigate the lung deposition and distribution pattern of TRIMBOW using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled TRIMBOW administered via pMDI in healthy volunteers, asthmatic and COPD patients |
| NCT03842904 ↗ | A Study Comparing the Effects of Trimbow to Fostair in COPD | Completed | Chiesi UK | Phase 4 | 2018-12-13 | A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD). |
| NCT03842904 ↗ | A Study Comparing the Effects of Trimbow to Fostair in COPD | Completed | Medicines Evaluation Unit Ltd | Phase 4 | 2018-12-13 | A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation and expiratory flow limitation in moderate to severe chronic obstructive pulmonary disease (COPD). |
| NCT04671355 ↗ | TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD | Withdrawn | Chiesi Farmaceutici S.p.A. | Phase 4 | 2021-10-04 | Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD). |
| NCT04737655 ↗ | Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care | Not yet recruiting | PARZIBUT Gilles | Phase 4 | 2021-02-15 | Objective: To evaluate non-inferiority of Trimbow, an approved therapy for treatment of severe COPD, in ICU compared to the standard of care which is based on the same therapeutic approach. Study location: CHU Sart-Tilman, 4000 Liège, Belgium Study duration: 2 years Type : Interventional Methodology: Prospective clinical trial Number of patients: 200 (randomized 1:1) Main Inclusion criteria : - Maintenance therapy (LAMA or LABA) for COPD - Age >18 - Admission for AE of COPD - Signed Inform consent - Admitted in ICU >24h |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIMBOW
Condition Name
Clinical Trial Locations for TRIMBOW
Trials by Country
Clinical Trial Progress for TRIMBOW
Clinical Trial Phase
Clinical Trial Sponsors for TRIMBOW
Sponsor Name
